Welcome to our dedicated page for MoonLake Immunotherapeutics SEC filings (Ticker: MLTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MoonLake Immunotherapeutics (NASDAQ: MLTX) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as it develops sonelokimab, an investigational Nanobody® targeting IL‑17A and IL‑17F, for inflammatory skin and joint diseases. As a Cayman Islands–incorporated issuer listed on Nasdaq, MoonLake files reports and current event disclosures with the Securities and Exchange Commission that document material agreements, clinical milestones and financial results.
Among the key documents are Form 8‑K filings, which MoonLake uses to report material events such as the pricing of an underwritten offering of Class A ordinary shares, entry into a term loan facility, and press releases announcing quarterly financial results. 8‑K filings also reference clinical and regulatory developments, including Phase 3 VELA trial data in hidradenitis suppurativa (HS), Phase 2 LEDA results in palmoplantar pustulosis (PPP), interim analyses from the VELA‑TEEN adolescent HS study, and updates on the broader sonelokimab trial portfolio.
Investors can use this page to review how MoonLake describes its financial condition, capital structure and key agreements in official SEC documents. Filings may incorporate press releases that summarize cash balances, research and development spending, non-dilutive financing arrangements, and expectations regarding the funding of Phase 2 and Phase 3 programs in HS, psoriatic arthritis (PsA), axial spondyloarthritis (axSpA) and PPP.
Stock Titan enhances these filings with AI-powered tools that help interpret lengthy disclosures. Users can quickly identify the purpose of a given 8‑K, locate references to clinical trial data, and understand the context of equity offerings or debt facilities. Real-time updates from EDGAR ensure that new MoonLake filings appear promptly, while structured access makes it easier to follow how regulatory, clinical and financing developments are reflected in the company’s official record.
MoonLake Immunotherapeutics furnished an 8-K announcing a press release with its financial results for the quarter ended September 30, 2025 and clinical program updates. Under Item 2.02, the company reported Q3 2025 results via Exhibit 99.1. Under Item 7.01, it highlighted results from the Phase 2 LEDA trial of Sonelokimab (SLK) in adult palmoplantar pustulosis and an interim analysis from the Phase 3 VELA-TEEN trial in adolescents with hidradenitis suppurativa. The Item 7.01 information is being furnished and is not deemed filed under Section 18.
Insider purchase by MoonLake Immunotherapeutics CFO. The filing shows Matthias Bodenstedt, the company’s Chief Financial Officer and a director, purchased 10,870 Class A ordinary shares on
MoonLake Immunotherapeutics - Schedule 13G/A summary: This filing reports that Bihua Chen, acting through Cormorant Asset Management-related funds, beneficially owns 1,994,173 Class A Ordinary Shares, representing 3.14% of the outstanding Class A shares. The holder reports shared voting and dispositive power over these shares and no sole voting or dispositive power. The percentage calculation references the issuer's reported outstanding Class A share count of 63,501,402. The filer certifies the securities are held in the ordinary course of business and not to influence control of the issuer.
MoonLake Immunotherapeutics reported that it has released week 16 results from its Phase 3 VELA-1 and VELA-2 trials, which are part of its registrational global program in patients with moderate-to-severe hidradenitis suppurativa, a chronic inflammatory skin disease. These late-stage studies are important because they test whether the company’s therapy can provide meaningful benefit in a difficult-to-treat population.
The company issued a press release with the data on September 28, 2025 and scheduled a webcast on September 29, 2025 at 8:00 a.m. Eastern Time to review the results. The press release detailing the clinical data has been filed as an exhibit to this report, giving investors and clinicians access to the full outcome of the VELA-1 and VELA-2 trials.
Kristian Reich, Chief Scientific Officer and director of MoonLake Immunotherapeutics (MLTX), executed an equity exchange on 09/02/2025. He surrendered 1,456 common shares of MoonLake AG in exchange for 48,978 Class A ordinary shares of the issuer, and as part of the transaction 48,978 Class C ordinary shares were automatically cancelled for no consideration. The filing discloses that 10,000 MoonLake AG shares held by the reporting person remain subject to a reverse-vesting schedule that completes on January 18, 2026. The filing also states that JeruCON Beratungsgesellschaft mbH owns 2,974,551 Class A ordinary shares, of which Dr. Reich may be deemed an indirect beneficial owner.
Avoro Capital Advisors LLC and Behzad Aghazadeh filed a Schedule 13G disclosing beneficial ownership of 4,150,000 Class A ordinary shares of MoonLake Immunotherapeutics, representing 6.5% of the class. Avoro reports sole voting and sole dispositive power over these shares and states they were acquired for investment purposes on behalf of Avoro Life Sciences Fund LLC.
The filing identifies Dr. Behzad Aghazadeh as the portfolio manager and controlling person of Avoro with the same voting and dispositive powers. The reporting persons certify the holdings are held in the ordinary course of business and not for the purpose of changing or influencing control. A Joint Filing Agreement is attached as an exhibit.
On 08/05/2025 FMR LLC, the parent of Fidelity Investments, together with Abigail P. Johnson, filed Amendment No. 3 to Schedule 13G for MoonLake Immunotherapeutics (MLTX). The filing discloses beneficial ownership of 5,703,048.73 Class A shares (CUSIP 61559X104) as of 06/30/2025, representing 9.0 % of the outstanding class.
The filer reports sole voting power over 5,700,976.70 shares and sole dispositive power over 5,703,048.73 shares; there is no shared voting or dispositive power. The schedule is submitted under Rule 13d-1(b) with FMR classified as a “HC” (parent holding company/control person) and Johnson as “IN” (individual), indicating a passive investment rather than an attempt to influence control. The certification confirms the shares were acquired and are held in the ordinary course of business. No group arrangements, control-changing intentions, or additional financial terms are disclosed.